PROCEPT BioRobotics Corporation (PRCT)
| Market Cap | 1.63B -48.9% |
| Revenue (ttm) | 322.02M +29.3% |
| Net Income | -102.47M |
| EPS | -1.83 |
| Shares Out | 56.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 579,554 |
| Open | 28.40 |
| Previous Close | 28.35 |
| Day's Range | 28.38 - 29.36 |
| 52-Week Range | 19.35 - 64.92 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 30.44 (+6.25%) |
| Earnings Date | Apr 29, 2026 |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hype... [Read more]
Financial Performance
In 2025, PROCEPT BioRobotics's revenue was $308.05 million, an increase of 37.22% compared to the previous year's $224.50 million. Losses were -$95.57 million, 4.55% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PRCT stock is "Buy." The 12-month stock price target is $30.44, which is an increase of 6.25% from the latest price.
News
PROCEPT BioRobotics Transcript: 46th Annual William Blair Growth Stock Conference
Significant growth opportunities exist in the BPH and prostate cancer markets, with operational realignment and launch teams accelerating system adoption and utilization. Financial targets include EBITDA profitability by Q4, 65%+ gross margins, and robust revenue growth, supported by new clinical trials and product upgrades.
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the r...
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of...
PROCEPT BioRobotics Transcript: Bank of America Global Healthcare Conference 2026
Q1 revenue and margins exceeded expectations, with strong system placements and pricing. Commercial realignment and launch teams are driving growth, while patient education and targeted marketing aim to expand adoption. Margin expansion and positive EBITDA are on track, and the prostate cancer trial presents a significant future opportunity.
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solu...
Procept BioRobotics price target raised to $35 from $28 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Procept BioRobotics (PRCT) to $35 from $28 and keeps an Overweight rating on the shares. The firm notes the…
Procept BioRobotics price target raised to $28 from $27 at Baird
Baird raised the firm’s price target on Procept BioRobotics (PRCT) to $28 from $27 and keeps a Neutral rating on the shares. The firm updated its model following Q1 beat…
Procept BioRobotics affirms FY26 revenue $390M-$410M, consensus $395.9M
The company continues to expect full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period. The company continues to…
Procept BioRobotics reports Q1 EPS (56c), consensus (55c)
Reports Q1 revenue $83.1M, consensus $80.3M. The Company “recently received FDA clearance of its second-generation FirstAssist AI(TM) software, an advancement in personalized, image-guided planning fo...
PROCEPT BioRobotics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 20% year-over-year to $83.1 million, driven by strong U.S. and international performance, improved pricing, and operational realignment. Gross margin reached 65%, and full-year guidance was reiterated, with positive EBITDA expected in Q4.
PROCEPT BioRobotics Earnings release: Q1 2026
PROCEPT BioRobotics released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
PROCEPT BioRobotics Quarterly report: Q1 2026
PROCEPT BioRobotics has published its Q1 2026 quarterly earnings report on April 29, 2026.
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transf...
PROCEPT BioRobotics Proxy statement: Proxy filing
PROCEPT BioRobotics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
PROCEPT BioRobotics Proxy statement: Proxy filing
PROCEPT BioRobotics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transf...
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia Updated European Associati...
Procept BioRobotics announce international launch of HYDROS Robotic
Procept BioRobotics (PRCT) announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyper...
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platfor...
Procept BioRobotics initiated with a Neutral at Baird
Baird last night initiated coverage of Procept BioRobotics (PRCT) with a Neutral rating and $30 price target The firm says “several recent headwinds have set the company back,” which has…
Procept BioRobotics initiated with a Neutral at Baird
Baird analyst David Rescott initiated coverage of Procept BioRobotics (PRCT) with a Neutral rating and $30 price target
PROCEPT BioRobotics Transcript: TD Cowen 46th Annual Health Care Conference
New organizational structures and launch teams are driving faster system adoption and improved utilization. Inventory management has stabilized, and a replacement strategy for legacy systems is being developed. HYDROS systems show higher usage, and market expansion efforts target both procedure conversion and patient awareness.
Procept BioRobotics price target lowered to $30 from $62 at UBS
UBS analyst Danielle Antalffy lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $62 and keeps a Buy rating on the shares.
Procept BioRobotics price target lowered to $30 from $47 at Truist
Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst…
Ademi LLP Investigates Claims of Securities Fraud against PROCEPT BioRobotics Corporation
MILWAUKEE, Feb. 26, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics (NASDAQ: PRCT). The investigation results from inaccurate statements PR...